Ignite Creation Date:
2025-12-25 @ 2:27 AM
Ignite Modification Date:
2026-02-12 @ 8:31 AM
Study NCT ID:
NCT05585034
Status:
COMPLETED
Last Update Posted:
2025-08-07
First Post:
2022-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Sponsor:
Xencor, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Melanoma Excluding Uveal Melanoma | View |
| None | Non-small Cell Lung Cancer, Squamous or Non-squamous | View |
| None | Urothelial Carcinoma | View |
| None | Renal Cell Carcinoma, Clear Cell | View |
| None | Castration-resistant Prostate Cancer | View |
| None | Ovarian Cancer, Epithelial | View |
| None | TNBC - Triple-Negative Breast Cancer | View |
| None | Colorectal Cancer | View |
Keywords: